Murphy Capital Management Inc. Trims Stake in Celgene Co. (CELG)

Murphy Capital Management Inc. decreased its holdings in Celgene Co. (NASDAQ:CELG) by 4.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 26,383 shares of the biopharmaceutical company’s stock after selling 1,321 shares during the quarter. Murphy Capital Management Inc.’s holdings in Celgene were worth $3,847,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Rockefeller Financial Services Inc. raised its holdings in shares of Celgene by 70.4% in the 3rd quarter. Rockefeller Financial Services Inc. now owns 22,614 shares of the biopharmaceutical company’s stock worth $3,298,000 after purchasing an additional 9,345 shares during the period. Meeder Asset Management Inc. raised its holdings in shares of Celgene by 135.2% during the 3rd quarter. Meeder Asset Management Inc. now owns 14,089 shares of the biopharmaceutical company’s stock valued at $2,054,000 after buying an additional 8,098 shares during the period. First National Bank of Hutchinson raised its holdings in shares of Celgene by 57.6% during the 3rd quarter. First National Bank of Hutchinson now owns 5,136 shares of the biopharmaceutical company’s stock valued at $750,000 after buying an additional 1,878 shares during the period. Fisher Asset Management LLC raised its holdings in shares of Celgene by 0.7% during the 3rd quarter. Fisher Asset Management LLC now owns 265,695 shares of the biopharmaceutical company’s stock valued at $38,744,000 after buying an additional 1,766 shares during the period. Finally, Wendell David Associates Inc. raised its holdings in shares of Celgene by 4.2% during the 3rd quarter. Wendell David Associates Inc. now owns 92,735 shares of the biopharmaceutical company’s stock valued at $13,523,000 after buying an additional 3,735 shares during the period. 79.74% of the stock is currently owned by institutional investors.

Celgene Co. (NASDAQ:CELG) traded down $0.88 during mid-day trading on Thursday, reaching $104.58. The company’s stock had a trading volume of 7,010,000 shares, compared to its average volume of 6,250,000. The company has a market cap of $82,340.00, a PE ratio of 24.67, a PEG ratio of 0.68 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. Celgene Co. has a 52-week low of $94.55 and a 52-week high of $147.17.

Celgene (NASDAQ:CELG) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a return on equity of 43.32% and a net margin of 30.06%. The company’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.58 EPS. equities analysts expect that Celgene Co. will post 6.68 earnings per share for the current year.

A number of equities research analysts have weighed in on CELG shares. Royal Bank of Canada lowered their price objective on Celgene from $166.00 to $148.00 and set a “top pick” rating for the company in a research note on Friday, October 27th. Leerink Swann reiterated a “buy” rating and issued a $156.00 target price on shares of Celgene in a research report on Friday, October 20th. Morgan Stanley decreased their target price on Celgene from $120.00 to $115.00 and set an “underweight” rating for the company in a research report on Monday, October 23rd. SunTrust Banks reduced their price objective on Celgene from $156.00 to $127.00 and set a “buy” rating for the company in a research report on Friday, October 27th. Finally, William Blair restated an “outperform” rating on shares of Celgene in a research report on Friday, October 20th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and nineteen have given a buy rating to the company’s stock. Celgene presently has a consensus rating of “Buy” and a consensus target price of $131.18.

COPYRIGHT VIOLATION WARNING: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/11/celgene-co-celg-shares-sold-by-murphy-capital-management-inc.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply